DBV Technologies stock among SBF 120 leaders, but -21.5% over three months
The Châtillon biotech is resisting mounting pressure on its monthly performance, posting one of the strongest gains in the broad index on Wednesday. The stock is nonetheless evolving in a still unfavorable technical context, remaining anchored below its main moving averages despite a weekly rebound.
A weekly rebound of more than 5% that fails to erase the quarterly decline
DBV Technologies advances 1.87% to €2.18 during the session, ranking among the top performers of the SBF 120 while the broad index gains just 0.05%. The increase is part of a positive momentum that began during the week, with a gain of more than 5% over seven days. It compensates, however, only a fraction of the 12.73% monthly decline nor, all the more so, the 21.64% drop accumulated over three months.
On a one-year basis, the stock remains in significantly positive territory with a gain of 35.07%, a sign that the recent correction is part of a still favorable annual balance. The CAC 40, nearly stable at 8,159.79 points during the session, offers little direction to stocks like DBV Technologies, whose price drivers remain more closely tied to regulatory developments. When publishing first-half 2026 results (July 16, 2026), the company indicated it anticipated submitting its regulatory file (BLA) to the FDA in the third quarter of 2026, with cash reserves covering through the third quarter of 2027.
Moving averages well above the price and short positions in slight progression
The technical setup remains constrained. The price at €2.18 is below the 20-day MA at €2.28 (a gap of 4.39%) and notably below the 50-day MA at €2.39 (a gap of 8.79%), while the 200-day MA at €3.13 remains more than 30% above the current price. The RSI at 39 illustrates accumulated selling pressure on the stock without tipping into clear oversold territory, still offering room before reaching the €2.07 support level.
According to reported declarations, three funds cumulatively hold 3.70% of the capital sold short, a level up 0.38 points over thirty days (against 3.32% a month ago). This figure, above the 3% threshold, demonstrates an institutional presence positioned against the stock that deserves to be monitored, without in itself indicating the scale or imminence of a reversal. The €2.57 resistance represents the next level to overcome for the weekly momentum to continue.
